Opthea Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
7,162.00
18,435.60
14,486.40
51,959.90
32,510.20
Total Accounts Receivable
2,705.90
3,345.40
1,977.10
3,218.70
12,411.00
Other Current Assets
113.10
140.60
182.00
154.00
292.30
Total Current Assets
9,981.00
21,921.70
16,645.50
55,332.60
45,213.50
Net Property, Plant & Equipment
148.80
110.20
91.20
63.80
69.10
Total Investments and Advances
2,275.40
2,041.00
315.90
1,148.20
793.30
Total Assets
12,461.30
24,072.90
17,052.60
56,544.70
46,075.90
Accounts Payable
1,326.50
-
-
-
7,223.00
Income Tax Payable
80.80
43.80
45.90
47.30
52.50
Other Current Liabilities
357.70
2,204.40
1,966.20
1,955.40
588.50
Total Current Liabilities
1,765.00
2,248.20
2,012.20
2,002.70
7,864.00
Provision for Risks & Charges
86.20
41.10
16.80
24.80
38.50
Other Liabilities
74.80
61.90
45.40
25.20
0.90
Total Liabilities
1,982.10
2,351.20
2,074.40
2,052.70
7,903.40
Common Equity (Total)
9,535.20
20,904.00
14,978.20
54,492.00
38,172.40
Total Shareholders' Equity
9,535.20
20,904.00
14,978.20
54,492.00
38,172.40
Total Equity
10,479.30
21,721.60
14,978.20
54,492.00
38,172.40
Liabilities & Shareholders' Equity
12,461.30
24,072.90
17,052.60
56,544.70
46,075.90
Accumulated Minority Interest
944.10
817.60
-
-
-

About Opthea

View Profile
Address
650 Chapel Street
South Yarra Victoria (VIC) 3141
Australia
Employees -
Website http://www.opthea.com
Updated 07/08/2019
Opthea Ltd. is engaged in developing biological therapeutics for cancer and other serious diseases. It is a biologics drug developer building on its significant intellectual property portfolio around Vascular Endothelial Growth Factor C and D angiogenic molecules and R3. The company focuses on vascular endothelial growth factors to develop truly novel therapies to extend and improve the lives of cancer sufferers.